Serosurveillance inobata nekufungidzira kuwanda kwemasoja ekudzivirira chirwere muhuwandu kurwisa imwe pathogen.Inobatsira kuyera kusadzivirirwa kwehuwandu mushure mekutapukirwa kana kubayiwa uye ine epidemiological utility mukuyera njodzi dzekutapurirana uye huwandu hwekudzivirirwa kwehuwandu.Mune yazvino chirwere chekoronavirus chirwere 2019 (COVID-19) denda, serosurvey yakaita basa rakakosha mukuongorora dhigirii chairo reacute acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utachiona muvanhu vakasiyana.Izvo zvakare zvakabatsira kumisikidza epidemiologic zviratidzo, semuenzaniso, iyo hutachiona hwekuuraya huwandu (IFR).
Pakupera kwa2020, mazana mana serosurveys akange aburitswa.Zvidzidzo izvi zvaive zvakavakirwa pamhando dzakasiyana dzemaimmunoassays ayo akagadzirirwa kuongorora masoja ekudzivirira chirwere kubva kuSARS-CoV-2, achinyanya kunanga zvese kana chikamu che spike (S) uye nucleocapsid (N) mapuroteni eSARS-CoV-2.Mumamiriro azvino eCCIDID-19 denda, masaisai edenda anotevedzana anga achiitika munzvimbo dzakasiyana dzepasi, achitapura musanganiswa wakasiyana wehuwandu pane imwe nguva yakapihwa panguva.Chiitiko ichi chakadenha SARS-CoV-2 serosurveillance nekuda kwekuwedzera heterogeneous immunological landscape.
Masayendisiti akaona kuti anti-SARS-CoV-2 antibody mazinga ane tsika yekuora mushure menguva yekupora.Chiitiko chakadaro chinowedzera mikana yemigumisiro yakaipa ne immunoassays.Aya manyepo anogona kukanganisa kuomarara kwehuwandu hwehutachiona kunze kwekunge aonekwa nekugadziriswa nekukurumidza.Pamusoro pezvo, post-infection antibody kinetics inoratidzika zvakasiyana zvichienderana nekuoma kwehutachiona - yakanyanya kusimba hutachiona hweCCIDID-19 hunoita kuti huwedzere kuwedzera kwehuwandu hwemasoja ekudzivirira chirwere kana tichienzanisa nehunyoro kana asymptomatic hutachiona.
Zvidzidzo zvakawanda zvakaratidza antibody kinetics kwemwedzi mitanhatu mushure mekutapukirwa.Zvidzidzo izvi zvakaona kuti ruzhinji rwevanhu munharaunda dzakatapukirwa neSARS-CoV-2 vakaratidza hunyoro kana asymptomatic.Vatsvaguri vanotenda kuti zvakakosha kuyera shanduko yemazinga emasoja ekudzivirira chirwere, uchishandisa anowanikwa ma immunoassays, pahupamhi hwehupamhi hwehutachiwana.Zera raionekwawo sechinhu chakakosha muzvidzidzo izvi.
Muchidzidzo chechangobva kuitika, masayendisiti akaverengera anti-SARS-CoV-2 antibody mazinga anosvika mwedzi 9 mushure mekutapukirwa, uye vakaburitsa zvavakawana mumedRxiv* preprint server.Muchidzidzo chazvino, boka revanhu vane seropositive rakanyorerwa kuburikidza neserosurveys yakaitwa muGeneva, Switzerland.Vatsvagiri vakashandisa matatu akasiyana ma immunoassays, anoti, semiquantitative anti-S1 ELISA yekuona IgG (inonzi EI), iyo yakawanda Elecsys anti-RBD (inonzi, Roche-S) uye semiquantitative Elecsys anti-N (inonzi Roche- N).Tsvagiridzo yazvino inopa nzwisiso yakakosha muhuwandu-yakavakirwa serologic zvidzidzo uye inoratidza kuomarara kwenzvimbo yekudzivirira nekuda kwemusanganiswa weazvino uye distal COVID-19 hutachiona, pamwe nekudzivirira.
Chidzidzo ichi chiri kutariswa chakataura kuti vanhu vakabata COVID-19 vaine zviratidzo zvinyoro kana kuti vaive asymptomatic, vakaratidza kuvepo kwemasoja ekudzivirira chirwere.Aya masoja ekudzivirira chirwere akananga kunucleocapsid (N) kana spike (S) mapuroteni eSARS-CoV-2 uye akawanikwa achishingirira kweinenge mwedzi misere mushure mekutapukirwa.Zvisinei, kuonekwa kwavo kunonyanya kuenderana nesarudzo ye immunoassay.Vatsvagiri vakaona kuti zviyero zvekutanga zvemasoja ekudzivirira chirwere, akatorwa kubva kune vatori vechikamu mukati memwedzi mina nehafu yeCCIDID-19, aienderana mumhando dzese nhatu dzema immunoassays akashandiswa muchidzidzo ichi.Nekudaro, mushure memwedzi mina yekutanga, uye kusvika kumwedzi misere mushure mekutapukirwa, mibairo yakasiya-siyana pakuongorora.
Tsvagiridzo iyi yakaratidza kuti mune yeEI IgG assay, mumwe muvatori vechikamu vana aive nesero-yakadzoserwa.Nekudaro, kune mamwe ma immunoassays, senge Roche anti-N uye anti-RBD yakazara Ig bvunzo, mashoma kana asina sero-reversions akaonekwa kune imwecheteyo sampuli.Kunyangwe vatori vechikamu vane hutachiona hunyoro, avo vaimbofungidzirwa kuti vape mhinduro dzakasimba dzekudzivirira zvirwere, vakaratidza kunzwisiswa vachishandisa anti-RBD uye anti-N yakazara Ig Roche bvunzo.Ose maassays akaramba aine hanya kweanopfuura mwedzi 8 mushure mekutapukirwa.Nekudaro, mhedzisiro iyi yakaratidza kuti ese maRoche immunoassays akanyanya kukodzera kufungidzira seroprevalence mushure menguva refu mushure mekutanga kutapukirwa.
Zvadaro, vachishandisa simulation ongororo, vatsvakurudzi vakagumisa kuti pasina yakarurama quantification nzira, kunyanya, tichifunga nguva-siyana assay senitivity, seroprevalence ongororo kwaisazova yakarurama.Izvi zvinoita kuti tisatarisirwe huwandu chaihwo hwehurwere hunowedzera muhuwandu.Ichi chidzidzo che immunoassay chakaratidza kuvepo kwekusiyana kweseropositivity rates pakati pekutengesa-kunowanikwa bvunzo.
Zvinofanira kucherechedzwa kuti pane zvakawanda zvinogumira pachidzidzo ichi.Semuenzaniso, reagent inoshandiswa pakuitisa EI assay kune ese ekutanga (yekutanga kana 1st bvunzo) uye yekutevera (yechipiri bvunzo yevamwechete vavhoti) masampula mukati menguva yakatarwa aive akasiyana.Chimwe chinodzivirirwa pachidzidzo ichi ndechekuti mapoka acho haana kusanganisira vana.Kusvika iye zvino, hapana humbowo hwenguva refu antibody dynamics muvana yakanyorwa.
Nguva yekutumira: Mar-24-2021